BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eighteen research firms that are currently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $137.91.

Several research firms have weighed in on BNTX. Citigroup reaffirmed a "buy" rating and issued a $140.00 price target (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners set a $112.00 target price on shares of BioNTech in a research report on Monday, June 2nd. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $138.00 price objective on shares of BioNTech in a report on Wednesday, June 25th.

BioNTech Price Performance

BioNTech stock traded down $1.03 during midday trading on Thursday, reaching $112.89. 521,908 shares of the stock were exchanged, compared to its average volume of 943,160. The company's fifty day moving average is $103.56 and its 200-day moving average is $106.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market cap of $27.14 billion, a PE ratio of -33.20 and a beta of 1.29.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently made changes to their positions in BNTX. Daiwa Securities Group Inc. raised its position in shares of BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after acquiring an additional 128 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after buying an additional 150 shares in the last quarter. Probity Advisors Inc. boosted its stake in BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after purchasing an additional 154 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in BioNTech by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock worth $227,000 after buying an additional 209 shares in the last quarter. Finally, Midwest Professional Planners LTD. grew its stake in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after acquiring an additional 222 shares during the period. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.